(Q37287552)

19 August 2017

title

Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries (English)

1 reference

19 August 2017

1 reference

1 reference

Nagi S El Saghir

1

1 reference

19 August 2017

Alexandru Eniu

2

1 reference

19 August 2017

Robert W Carlson

3

1 reference

19 August 2017

Zeba Aziz

4

1 reference

19 August 2017

Daniel Vorobiof

5

1 reference

19 August 2017

Gabriel N Hortobagyi

6

1 reference

19 August 2017

Breast Health Global Initiative Systemic Therapy Focus Group

7

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

113

1 reference

19 August 2017

issue

8 Suppl

1 reference

19 August 2017

page(s)

2315-2324

1 reference

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Use of statistics to assess the global burden of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

The global breast cancer burden: variations in epidemiology and survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Trends in breast cancer by race and ethnicity: update 2006.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Spectrum of breast cancer in Asian women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Revision of the American Joint Committee on Cancer staging system for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Preoperative chemotherapy treatment of breast cancer--a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Docetaxel/anthracycline combinations for breast cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Primary systemic therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Guidelines on the standards for the training of specialised health professionals dealing with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23836

7 January 2021

Identifiers

DOI

10.1002/CNCR.23836

1 reference

19 August 2017

1 reference